Rhythm Pharmaceuticals (RYTM) Preferred Stock Liabilities (2016 - 2026)

Rhythm Pharmaceuticals (RYTM) has 6 years of Preferred Stock Liabilities data on file, last reported at $114.7 million in Q1 2026.

• On a quarterly basis, Preferred Stock Liabilities fell 20.42% year-over-year to $114.7 million in Q1 2026; TTM through Mar 2026 was $114.7 million, a 20.42% decrease from a year earlier, with the FY2025 full-year figure at $131.0 million, down 8.31% from the prior year.
• Preferred Stock Liabilities for Q1 2026 stood at $114.7 million, down from $131.0 million in the prior quarter.
• Over the last five years, Preferred Stock Liabilities for RYTM reached as high as $146.9 million in Q3 2025 and fell as low as $1.6 million in Q2 2022.
• Historically, Preferred Stock Liabilities has averaged $123.1 million across 4 years, with a median of $141.5 million in 2024.
• Across the five-year window, Preferred Stock Liabilities grew 3.81% in 2025 and slipped 20.42% in 2026, its largest moves.
• Year by year, Preferred Stock Liabilities stood at $1.6 million in 2022, then surged by 8882.39% to $142.8 million in 2024, then dropped by 8.31% to $131.0 million in 2025, then retreated by 12.41% to $114.7 million in 2026.
• Per Business Quant data, the three most recent Preferred Stock Liabilities figures were $114.7 million in Q1 2026, $131.0 million in Q4 2025, and $146.9 million in Q3 2025.